Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

305.12 +1.50 (+0.49%)
Streaming Delayed Price Updated: 3:40 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
1 Cash-Producing Stock with Exciting Potential and 2 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Tuesday's session: gap up and gap down stock in the S&P500 index
Stay updated with the S&P500 gap up and gap down stocks on Tuesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue... 
Via StockStory
Topics Economy World Trade
Exposures Supply Chain Tariff
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
3 Medical Technology Stocks Outperforming in 2025
Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns. 
Via MarketBeat
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
3 Reasons Investors Love Insulet (PODD)
While the broader market has struggled with the S&P 500 down 1.8% since December 2024, Insulet has surged ahead as its stock price has climbed by 18.9% to $318.02 per share. This was partly thanks to... 
Via StockStory
Topics Stocks
Exposures US Equities
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Insulet (NASDAQ:PODD) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock with Technical Breakout Potential
INSULET CORP (NASDAQ:PODD) shows strong growth fundamentals and a bullish technical pattern, making it a stock worth watching for investors seeking growth opportunities. 
Via Chartmill
1 Surging Stock with Exciting Potential and 2 to Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
5 Analysts Assess Insulet: What You Need To Know
Via Benzinga
INSULET CORP (NASDAQ:PODD) – A Strong Growth Stock Meeting Minervini’s Trend Template
INSULET CORP (NASDAQ:PODD) meets Minervini’s Trend Template with strong technicals and high growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Insulet's earnings and upgraded guidance recently propelled its stock to S&P 500 leadership, showcasing strong execution in the diabetes care market. 
Via MarketBeat
Topics Stocks
Exposures US Equities
1 Mid-Cap Stock to Target This Week and 2 to Avoid
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today
Via Benzinga
The Trade Desk, Walt Disney, And Hims & Hers Health Are Among Top 11 Large-Cap Gainers Last Week (May 5-May 9): Are The Others In Your Portfolio?
Top-performing large-cap stocks last week: TTD, HIMS, PODD, FTAI, ULS, UI, ROK, TOST, DIS, MCHP, and ARMK. Analysts raised price forecasts. 
Via Benzinga
Stay informed with the top movers within the S&P500 index on Friday.
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Why Insulet (PODD) Stock Is Trading Up Today
Shares of insulin delivery company Insulet Corporation (NASDAQ:PODD) jumped 20.7% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat... 
Via StockStory
What's going on in today's session: S&P500 movers
Let's delve into the developments on the US markets in the middle of the day on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Stocks Slip As Gold Rebounds To $3,330, Bitcoin Holds $102,000: What's Driving Markets Friday?
Wall Street traded slightly lower by midday Friday, as investors adopted a wait-and-see stance ahead of a potential trade breakthrough, with high-stakes negotiations between U.S. officials—led by... 
Via Benzinga
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad
Insulet beat Q1 expectations with $569 million in revenue and raised its 2025 outlook as global Omnipod adoption drives double-digit growth. 
Via Benzinga
Wondering what's happening in today's S&P500 pre-market session?
Pre-market stock analysis of S&P500 stocks on 2025-05-09: top gainers and losers in today's session. 
Via Chartmill
Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday
Via Benzinga
Which S&P500 stocks are showing activity after the closing bell on Thursday?
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
Insulet’s (NASDAQ:PODD) Q1: Strong Sales, Stock Soars
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 28.8% year on year to $569 million. On top of that, next... 
Via StockStory
Insulet Jumps After Beating Quarterly Forecasts, Raising 2025 Expectations
Insulet stock jumped late Thursday after the insulin pump-maker beat first-quarter forecasts and raised its sales outlook. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.